Boston Scientific (NYSE:BSX) Shares Gap Down – Should You Sell?

Boston Scientific Corporation (NYSE:BSX)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $49.86, but opened at $47.00. Boston Scientific shares last traded at $47.7710, with a volume of 8,395,832 shares changing hands.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
• Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
• Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
• Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

Analyst Upgrades and Downgrades

A number of analysts have recently commented on BSX shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Royal Bank Of Canada decreased their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Needham & Company LLC reduced their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Price Performance

The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average price of $46.53 and a two-hundred day moving average price of $56.72. The firm has a market cap of $67.59 billion, a P/E ratio of 18.88, a PEG ratio of 1.05 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 over the last ninety days. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LP raised its position in Boston Scientific by 25.3% in the 2nd quarter. Corient Private Wealth LP now owns 233,728 shares of the medical equipment provider’s stock valued at $9,976,000 after buying an additional 47,125 shares during the last quarter. Amundi boosted its position in Boston Scientific by 1.2% during the 2nd quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after acquiring an additional 173,208 shares during the last quarter. Affinity Wealth LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $76,000. Brown Financial Advisors raised its holdings in shares of Boston Scientific by 59.0% in the second quarter. Brown Financial Advisors now owns 20,881 shares of the medical equipment provider’s stock valued at $891,000 after purchasing an additional 7,749 shares during the last quarter. Finally, California State Teachers Retirement System raised its holdings in shares of Boston Scientific by 4,113.5% in the second quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider’s stock valued at $4,136,078,000 after purchasing an additional 94,609,083 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.